Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Comments and Responses

Metformin and Heart Failure: Innocent Until Proven Guilty

Response to Inzucchi

  1. Sergio Muntoni, MD, PHD
  1. 1From the Center for Metabolic Diseases and Atherosclerosis of Cagliari, The ME.DI.CO. Association, Cagliari, Italy
  1. Address correspondence to Sergio Muntoni, MD, PhD, 29 Viale Merello, 09123 Cagliari, Italy. E-mail: sergiomuntoni{at}hotmail.com
Diabetes Care 2006 Mar; 29(3): 751-752. https://doi.org/10.2337/diacare.29.03.06.dc05-2259
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Response to Inzucchi

The editorial by Inzucchi (1) in the October 2005 issue of Diabetes Care on the effects of metformin in type 2 diabetic patients with heart failure deals in a masterly manner with the choice of the most suitable treatment of this condition. Since both diabetic heart failure and mechanism of metformin action are not completely understood, it is difficult, in the author’s opinion, to find a convincing explanation of the benefit from the use of this drug. However, as the contracting heart gets most of its energy from nonesterified fatty acids (FFAs), and even does so more in the insulin-resistant state of diabetes, the author correctly states that a drug that enhances the uptake of the more metabolically efficient glucose instead of FFA may improve the function of the failing heart.

What the author is not aware of is that the mechanism of shift from one substrate to another has just been demonstrated for metformin and the other biguanides. In fact, dose-dependent inhibition of long-chain fatty acid oxidation in red muscle restores the glucose oxidation when depressed by concurrent oxidation of palmitic acid; hence, the proposed definition of biguanides as drugs of the Randle’s cycle (2,3).

Fischer et al. (4) describe increased content of glucose transporters GLUT1 and GLUT4 produced by metformin in heart cells.

Essop and Opie (5) stress the concept that high blood FFAs, especially in the presence of a hyperadrenergic state, can damage the ischemic myocardium and that agents that inhibit myocardial FFA oxidation should improve the work efficiency of the failing heart.

In conclusion, in my opinion there is good evidence that the beneficial effect of metformin in heart failure in type 2 diabetic patients rests on the same underlying mechanism shared by other well-known effects of the drug, i.e., increased utilization of glucose by red muscle and hindered gluconeogenesis in liver, as consequences of depressed fatty acid oxidation (2,3).

Footnotes

  • DIABETES CARE

References

  1. ↵
    Inzucchi SE: Metformin and heart failure: innocent until proven guilty (Editorial). Diabetes Care 28: 2585–2587, 2005
    OpenUrlFREE Full Text
  2. ↵
    Muntoni S: Inhibition of fatty acid oxidation by biguanides: implications for metabolic physiopathology. Adv Lipid Res 12: 311–377, 1974
    OpenUrlPubMed
  3. ↵
    Muntoni S: Metformin and fatty acids. Diabetes Care 22: 179–180, 1999
    OpenUrlFREE Full Text
  4. ↵
    Fischer Y, Thomas J, Rosen P, Kammermeier H: Action of metformin on glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology 136: 412–420, 1995
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Essop MF, Opie LH: Metabolic therapy for heart failure. Eur Heart J 25: 1765–1769, 2004
    OpenUrlFREE Full Text
PreviousNext
Back to top
Diabetes Care: 29 (3)

In this Issue

March 2006, 29(3)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Metformin and Heart Failure: Innocent Until Proven Guilty
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Metformin and Heart Failure: Innocent Until Proven Guilty
Sergio Muntoni
Diabetes Care Mar 2006, 29 (3) 751-752; DOI: 10.2337/diacare.29.03.06.dc05-2259

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Metformin and Heart Failure: Innocent Until Proven Guilty
Sergio Muntoni
Diabetes Care Mar 2006, 29 (3) 751-752; DOI: 10.2337/diacare.29.03.06.dc05-2259
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
  • Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
  • Flexible Intensive Insulin Therapy in Adults With Type 1 Diabetes and High Risk for Severe Hypoglycemia and Diabetic Ketoacidosis
Show more Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.